Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-15
2008-07-15
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000, C544S333000, C546S113000, C546S256000, C546S276400, C546S176000, C546S276700, C546S277400, C514S252020, C514S252050, C514S252040, C514S256000, C514S406000, C514S372000, C514S363000, C514S361000, C514S374000, C514S364000, C514S339000, C514S357000, C514S378000, C514S338000, C548S375100, C548S181000, C548S128000, C548S136000, C548S235000, C548S143000, C548S247000, C548S362500
Reexamination Certificate
active
07399765
ABSTRACT:
Compounds of formula (I)in-line-formulae description="In-line Formulae" end="lead"?Z-Ar1—Ar2 (I)in-line-formulae description="In-line Formulae" end="tail"?wherein Z is a diazabicyclic amine, Ar1is a 5- or 6-membered aromatic ring, and Ar2is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
REFERENCES:
patent: 6635645 (2003-10-01), Lochead et al.
patent: 2002/0013309 (2002-01-01), Miller et al.
patent: 2002/0019388 (2002-02-01), Schrimpf et al.
patent: 2003/0225268 (2003-12-01), Bunnelle et al.
patent: 2005/0131236 (2005-06-01), Peters et al.
patent: 00/34284 (2000-06-01), None
patent: 00/44755 (2000-08-01), None
patent: 00/71534 (2000-11-01), None
patent: 01/44243 (2001-06-01), None
patent: 01/81347 (2001-11-01), None
patent: 01/90109 (2001-11-01), None
patent: 02/02564 (2002-01-01), None
patent: 02/04446 (2002-01-01), None
patent: 02/44183 (2002-06-01), None
patent: 02/069901 (2002-09-01), None
patent: 02/096911 (2002-12-01), None
patent: 03/044020 (2003-05-01), None
patent: 03/094831 (2003-11-01), None
patent: 2004009589 (2004-01-01), None
Wolff, Burger's Medicinal Chemistry, 5thEd., vol. 1, pp. 975-977, 1994.
Adler et al., “Schizophrenia, sensory gating, and nicotinic receptors,” Schizophrenia Bulletin 24(2):189-202 (1998).
Cordero-Erausquin et al., “Tonic nicotinic modulation of serotoninergic transmission in the spinal cord,” PNAS 98(5):2803-2807 (2001).
Friedman et al., “A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia,” Biol. Psychiatry 51:349-357 (2002).
Heeschen et al., “Nicotine stimulates angiogenesis and promotes tumor growth and athersclerosis,” Nature Medicine 7(7):833-839 (2001).
Heeshcen et al., “A novel angiogenic pathway mediated by non-neuronal nicotinic acetycholine receptors,” Journal of Clinical Investigation 110(4):527-536 (2002).
Jonnala et al., “Relationship between the increased cell surface α7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists,” Journal of Neuroscience Research 66:565-572 (2001).
Kihara et al., “α7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A β-amyloid-induced neurotoxicity,” Journal of Biological Chemistry 276(17):13541-13546 (2001).
Leonard et al., “Smoking and schizophrenia: abnormal nicotinic receptor expression,” European Journal of Pharmacology 393:237-242 (2000).
Levin, “Nicotinic receptor subtypes and cognitive function,” J. Neurobiol. 53:633-640 (2002).
Liu et al., “β-Amyloid peptide blocks the reponse of α7-containing nicotinic receptors on hippocampal neurons,” PNAS 98(8):4734-4739 (2001).
Pirrung et al., “Photochmically removable silyl protecting groups,” J. Am. Chem. Soc. 123:3638-3643 (2001).
Rowley et al., “Current and novel approaches to the drug treatment of schizophrenia,” Journal of Medicinal Chemistry 44(4):477-501 (2001).
Shimohama et al., “Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage,” Brain Research 779:359-363 (1998).
Son et al., “Evidence suggesting that the mouse sperm acrosome reaction initiated by the zona pellucida involves an α7 nicotinic acetylcholine receptor,” Biology of Reproduction 68:1348-1351 (2003).
Stevens et al., “Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice,” Psychopharmacology 136:320-327 (1998).
Torii et al., “A versatile cycloaddition for the generation of pyrrolidine derivatives via C-N-C 1,3-dipoles,” Chemistry Letters 747-748 (1996).
Wang et al., “Nicotinic acetylcholine receptor α7 subunit is and essential regulator of inflammation,” Nature 421:384-388 (2003).
Wolff Me, “Burger's Medicinal Chemistry and Drug Discovery” Fifth Edition. John Wiley & Sons, 1995, pp. 975-977.
Banker et al., “Modern Pharmaceutics” Third Edition. Marcel Dekker, New York. 1996, p. 596.
Bunnelle William H.
Ji Jianguo
Li Tao
Mortell Kathleen H.
Nersesian Diana L.
Abbott Laboratories
Berch Mark L.
Jaisle Cecilia M
Vepachedu Sreenivasarao
LandOfFree
Substituted diazabicycloalkane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted diazabicycloalkane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted diazabicycloalkane derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814822